NCT06217146

A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.

A Two-part Study, Part I an Open-label; and Part II a Randomized Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MediCane's Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia Including Probable Alzheimer's Disease (AD)

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: M. H MediCane Ltd. · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This double-blind, placebo-controlled study is designed to assess the effectiveness of, MediCane's medical cannabis oil extracted from MediCane's proprietary strain into GMP-grade olive oil, as an add-on therapy to standard of care (SoC), in reducing agitation and disruptive behaviors in subjects with dementia including probable AD.

Conditions

• Agitation,Psychomotor
• Disruptive Behavior
• Dementia
• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	Medical Cannabis	MediCane's medical cannabis oil
DRUG	Placebo Oil	Placebo Oil

Timeline

• Start date: 2022-10-12
• Primary completion: 2024-03-10
• Completion: 2024-03-10
• First posted: 2024-01-22
• Last updated: 2024-06-27

Locations

3 sites across 1 country: Israel